BCRX vs. CERS
BCRX (BioCryst Pharmaceuticals, Inc.) and CERS (Cerus Corporation) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, BCRX returned 13.03%/yr vs -7.08%/yr for CERS. At a 0.25 correlation, their price movements are largely independent.
Performance
BCRX vs. CERS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BCRX achieves a 33.97% return, which is significantly lower than CERS's 51.46% return. Over the past 10 years, BCRX has outperformed CERS with an annualized return of 13.03%, while CERS has yielded a comparatively lower -7.08% annualized return.
BCRX
- 1D
- -2.52%
- 1M
- 20.11%
- 6M
- 41.22%
- YTD
- 33.97%
- 1Y
- 19.29%
- 3Y*
- 13.27%
- 5Y*
- -8.57%
- 10Y*
- 13.03%
CERS
- 1D
- -0.95%
- 1M
- 20.46%
- 6M
- 51.46%
- YTD
- 51.46%
- 1Y
- 115.17%
- 3Y*
- 8.69%
- 5Y*
- -9.95%
- 10Y*
- -7.08%
BCRX vs. CERS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BCRX BioCryst Pharmaceuticals, Inc. | 33.97% | 3.72% | 25.54% | -47.82% | -17.11% | 85.91% | 115.94% | -57.25% | 64.36% | -22.43% |
CERS Cerus Corporation | 51.46% | 33.77% | -28.70% | -40.82% | -46.40% | -1.59% | 63.98% | -16.77% | 50.00% | -22.30% |
Correlation
The correlation between BCRX and CERS is 0.22, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.22 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.28 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.36 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.34 |
Correlation (All Time) Calculated using the full available price history since Jan 31, 1997 | 0.25 |
The correlation between BCRX and CERS shifts across timeframes, from 0.22 (1 year) to 0.36 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
BCRX:
$2.19B
CERS:
$625.15M
BCRX:
-$2.02
CERS:
-$0.05
BCRX:
2.68
CERS:
2.77
BCRX:
$885.72M
CERS:
$216.56M
BCRX:
$167.34M
CERS:
$114.76M
BCRX:
-$374.88M
CERS:
-$2.69M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BCRX vs. CERS — Risk / Return Rank
BCRX
CERS
BCRX vs. CERS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for BioCryst Pharmaceuticals, Inc. (BCRX) and Cerus Corporation (CERS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BCRX | CERS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.97 | ||
| Sortino ratioReturn per unit of downside risk | -1.31 | ||
| Omega ratioGain probability vs. loss probability | 1.11 | 1.27 | -0.16 |
| Calmar ratioReturn relative to maximum drawdown | 0.58 | 2.66 | -2.07 |
| Martin ratioReturn relative to average drawdown | 1.20 | 6.53 | -5.33 |
Loading charts...
Drawdowns
BCRX vs. CERS - Drawdown Comparison
The maximum BCRX drawdown since its inception was -97.74%, roughly equal to the maximum CERS drawdown of -99.28%. Use the drawdown chart below to compare losses from any high point for BCRX and CERS.
Loading charts...
Drawdown Indicators
| BCRX | CERS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.74% | -99.28% | +1.54% |
Max Drawdown (1Y)Largest decline over 1 year | -30.36% | -38.32% | +7.96% |
Max Drawdown (3Y)Largest decline over 3 years | -47.85% | -62.21% | +14.36% |
Max Drawdown (5Y)Largest decline over 5 years | -79.10% | -85.37% | +6.27% |
Max Drawdown (10Y)Largest decline over 10 years | -83.69% | -86.45% | +2.76% |
Current DrawdownCurrent decline from peak | -68.46% | -96.12% | +27.66% |
Average DrawdownAverage peak-to-trough decline | -69.64% | -81.43% | +11.79% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 14.73% | 16.47% | -1.74% |
Volatility
BCRX vs. CERS - Volatility Comparison
BioCryst Pharmaceuticals, Inc. (BCRX) has a higher volatility of 15.21% compared to Cerus Corporation (CERS) at 14.10%. This indicates that BCRX's price experiences larger fluctuations and is considered to be riskier than CERS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BCRX | CERS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 15.21% | 14.10% | +1.11% |
Volatility (6M)Calculated over the trailing 6-month period | 36.41% | 54.56% | -18.15% |
Volatility (1Y)Calculated over the trailing 1-year period | 46.57% | 75.34% | -28.77% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 62.20% | 69.83% | -7.63% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 72.65% | 63.25% | +9.40% |
Dividends
BCRX vs. CERS - Dividend Comparison
Neither BCRX nor CERS has paid dividends to shareholders.
Financials
BCRX vs. CERS - Financials Comparison
This section allows you to compare key financial metrics between BioCryst Pharmaceuticals, Inc. and Cerus Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
BCRX and CERS have a correlation of 0.22, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BCRX has higher volatility (15.21%) compared to CERS (14.10%). In terms of maximum drawdown, BCRX dropped -97.74% vs CERS's -99.28%.
CERS currently has the higher Sharpe Ratio (1.35 vs 0.38), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BCRX and CERS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer